High materiality8/10
Goldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Why it may matterVerify against the original reporting
Analyst target implies substantial upside; bullish setup.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Goldman Sachs reiterates Buy rating on Summit Therapeutics; target set at $41; current price $15.48; priceChangeSinceSignal +$5.88.
- Goldman Sachs target to $41 with Buy rating; current price $15.48; price moved +$5.88 since signal.
Key facts
- 01
Target: $41
- 02
Posted price: $15.48
- 03
Analyst firm: Goldman Sachs
- 04
Analyst: Satoru Ogawa
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.